Tech Company Financing Transactions

EXIMIAS Pharmaceutical Funding Round

Birchmere Ventures, Cross Atlantic Capital Partners and Easton Capital participated in a $63.5 million Series D funding round for EXIMIAS Pharmaceutical. The round was announced on 3/31/2004.

Transaction Overview

Announced On
3/31/2004
Transaction Type
Venture Equity
Amount
$63,500,000
Round
Series D
Proceeds Purpose
Proceeds from this Series D financing will be used to enhance and further product development.

Company Information

Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
1055 Westlakes Drive 200
Berwyn, PA 19312
USA
Email Address
Overview
EXIMIAS Pharmaceutical Corporation focuses on the acquisition, development and commercialization of unique oncology and infectious disease products.
Profile
EXIMIAS Pharmaceutical LinkedIn Company Profile
Social Media
EXIMIAS Pharmaceutical Company Twitter Account
Company News
EXIMIAS Pharmaceutical News
Facebook
EXIMIAS Pharmaceutical on Facebook
YouTube
EXIMIAS Pharmaceutical on YouTube

Management Team

Title
Name
Email & Social
   LinkedIn Profile   Twitter Account   News   on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/31/2004: NextHop Technologies venture capital transaction
Next: 4/1/2004: LiveOps venture capital transaction

 

Share this article

 


News on VC Transactions

We report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary